Search

everythinglearnresearchcommunity

for

Search:↓

Concerns about a potential finasteride ban in the EU, possibly affecting the US, are discussed. Users doubt a ban, citing its widespread use and suggest alternatives like minoxidil and dutasteride.

A 35-year-old user shared their 11-month hair loss treatment success using Minoxidil and Propecia, noting their hair looks like it did at 25. Another user asked about the treatment, and the original poster confirmed using Propecia 1 mg and topical Minoxidil twice daily.

Kintor changed their KX-826 pictures on Amazon after backlash over fake images. Users are skeptical about the product's effectiveness and trustworthiness, with some preferring finasteride instead.

The conversation is about a user who got a perm after successfully treating their thinning hair, with mixed reactions from others on the appearance. Specific treatments used are not mentioned.

User suggests rotating scalp 180 degrees to address hair loss. Others discuss sanity, ethics, and similar procedures like scalp reduction and hair transplants.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

Hair loss theories discussed include poor blood flow, scalp tension, inflammation, and DHT. Treatments mentioned are massaging scalp, minoxidil, finasteride, and RU58841.

A user shared their experience after one year on Finasteride, noting both positive effects on hair retention and minor side effects like reduced libido and high blood pressure. They also emphasized the importance of quitting porn to improve sexual health and mentioned using Viagra to boost confidence.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

A 24-year-old woman being diagnosed with androgenic alopecia (AGA) who is scared and confused about her hair loss, and the treatment options of Minoxidil, finasteride, RU58841, spironolactone, and possibly a biopsy.

Hair loss itch is caused by DHT attacking follicles and stimulating nerves. Finasteride users who respond well don't experience this itch.

User experienced hair loss and tried Minoxidil, laser helmet, and Finasteride. Finasteride caused depression and sexual side effects, but user had a successful hair transplant.

Nutrafol is criticized for misleading advertising, as it doesn't effectively regrow hair. Effective treatments mentioned include minoxidil and finasteride.

The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.

The conversation is about purchasing Cb-03-01 for research purposes. The user seeks advice on where and how to buy it outside the U.S.

The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.

A US federal judge ruled that using patients' stem cells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stem cell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses concerns about a new rule affecting orders of hair loss treatments like Minoxidil, finasteride, and RU58841. Users are worried about the impact on their ability to obtain these products.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

The conversation is about a page stealing personal photos from a subreddit and selling a questionable oil as a hair loss treatment. Users are frustrated and discussing the theft of their images and ineffective moderation.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.

Cutting a 5 mg finasteride tablet into five equal parts and taking one piece daily is recommended for consistent dosing. This approach provides more stable DHT suppression than taking a full 5 mg tablet every five days.

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.